Henry VanBrocklin, PhD, received the Society of Nuclear Medicine and Moleular Imaging (SNMMI) Paul C. Aebersold Award, on June 25 during the society's annual meeting in Chicago.
The award recognizes outstanding achievement in basic science applied to nuclear medicine, according to the society.
Henry VanBrocklin, PhD.VanBrocklin is a professor in the department of radiology and biomedical imaging as well as director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging at the University of California, San Francisco. The SNMMI noted that VanBrocklin has led research on preparing and applying novel radiopharmaceuticals for over 30 years.
These efforts included receptor-based imaging agents for hormone receptors, growth factor receptors, neuroreceptors, and prostate-specific membrane antigens. He also led the development of imaging agents for cardiac blood flow and metabolism, according to the SNMMI.
Currently, VanBrocklin is evaluating a new agent to measure T-cell activation, F-18 fluoro-9-β-d-arabinofuranosylguanine (FaraG), and targeted antibodies to visualize viral reservoirs tied to HIV and long COVID-19, the society said.
VanBrocklin also currently serves as co-chair of the Coalition for PET Drug Manufacturers, an organization he co-founded to support interaction of the PET community with the U.S. Food and Drug Administration (FDA)
